Sucroferric oxyhydroxide

Drug Profile

Sucroferric oxyhydroxide

Alternative Names: Ferric oxyhydroxide; Ferrihydrite; Iron oxyhydroxide; P-TOL; PA-21; PA21-1; Phosphate binder - Vifor Pharma; suroferric oxyhydroxide tablets; Velphoro

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vifor Pharma
  • Developer Fresenius Medical Care; Kissei Pharmaceutical; Vifor Fresenius Medical Care Renal Pharma; Vifor Pharma
  • Class Ferric compounds; Hyperphosphataemia therapies
  • Mechanism of Action Phosphate binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 09 Jun 2017 Phase-II clinical trials in Hyperphosphataemia in Austria (PO) (NCT03010072)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Oct 2016 Hyogo College of Medicine and Kissei Pharmaceutical initiate a clinical trial for Hyperphosphataemia (in patients with chronic kidney disease on maintenance haemodialysis) in Japan (UMIN000023700)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top